1you

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1you" size="450" color="white" frame="true" align="right" spinBox="true" caption="1you, resolution 2.30&Aring;" /> '''Crystal structure o...)
Line 1: Line 1:
-
[[Image:1you.gif|left|200px]]<br />
+
[[Image:1you.gif|left|200px]]<br /><applet load="1you" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1you" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1you, resolution 2.30&Aring;" />
caption="1you, resolution 2.30&Aring;" />
'''Crystal structure of the catalytic domain of MMP-13 complexed with a potent pyrimidinetrione inhibitor'''<br />
'''Crystal structure of the catalytic domain of MMP-13 complexed with a potent pyrimidinetrione inhibitor'''<br />
==Overview==
==Overview==
-
Through the use of computational modeling, a series of, pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead, inhibitor identified through file screening. Incorporation of a biaryl, ether moiety at the C-5 position of the pyrimidinetrione ring resulted in, a dramatic enhancement of MMP-13 potency. Protein crystallography revealed, that this moiety binds in the S(1)(') pocket of the enzyme. Optimization, of the C-4 substituent of the terminal aromatic ring led to incorporation, of selectivity versus MMP-14 (MT-1 MMP). Structure activity relationships, of the biaryl ether substituent are presented as is pharmacokinetic data, for a compound that meets our in vitro potency and selectivity goals.
+
Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binds in the S(1)(') pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to incorporation of selectivity versus MMP-14 (MT-1 MMP). Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals.
==About this Structure==
==About this Structure==
-
1YOU is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with ZN, CA, SO4 and PFD as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1YOU OCA].
+
1YOU is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=ZN:'>ZN</scene>, <scene name='pdbligand=CA:'>CA</scene>, <scene name='pdbligand=SO4:'>SO4</scene> and <scene name='pdbligand=PFD:'>PFD</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YOU OCA].
==Reference==
==Reference==
Line 22: Line 21:
[[Category: metalloprotease]]
[[Category: metalloprotease]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:22:29 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:07:33 2008''

Revision as of 14:07, 21 February 2008


1you, resolution 2.30Å

Drag the structure with the mouse to rotate

Crystal structure of the catalytic domain of MMP-13 complexed with a potent pyrimidinetrione inhibitor

Overview

Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binds in the S(1)(') pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to incorporation of selectivity versus MMP-14 (MT-1 MMP). Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals.

About this Structure

1YOU is a Single protein structure of sequence from Homo sapiens with , , and as ligands. Full crystallographic information is available from OCA.

Reference

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14., Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA, Bioorg Med Chem Lett. 2005 Apr 1;15(7):1807-10. PMID:15780611

Page seeded by OCA on Thu Feb 21 16:07:33 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools